Stratpharma
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Stratpharma sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Stratpharma: 7 sponsored US clinical trials, 3 recruiting.
Stratpharma sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atrophic Vaginitis, with 2 trials.
Upper-quartile sponsor footprint
Stratpharma sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
NCT07346287
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090
Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
NCT05672901
Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
NCT05810194
StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis
NCT05553392
An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis
NCT05432154
Comparison of a Novel Wound Dressing Stratamed Versus Current Clinical Practice After Follicular Unit Extraction Hair Transplantation
NCT03843996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Stratpharma enrollment is open (later-stage tilt)
3 recruiting of 7 indexed (43% open); 3 completed (43%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Atrophic Vaginitis (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Stratpharma: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Stratpharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Stratpharma page
7 registered trials is a research-attention snapshot, not an endorsement of Stratpharma or any single study.
- 3 of Stratpharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atrophic Vaginitis is the condition Stratpharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atrophic Vaginitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Stratpharma pipeline card: 7 registered trials from official public datasets.Report a data error.